Zepp Health Corporation (NYSE: ZEPP) saw its stock plummet 5.58% in pre-market trading on Wednesday, following the release of its third-quarter 2025 financial results. The sharp decline comes despite the company reporting significant revenue growth, suggesting investors may have concerns about profitability and future outlook.
The wearable technology company announced unaudited financial results for Q3 2025 after market close on Tuesday, with revenue reaching $75.8 million, representing a substantial 78.5% year-over-year increase. Zepp Health also reported achieving adjusted operating income breakeven, marking a key milestone on its path to sustained profitability.
However, several factors may be contributing to the negative market reaction:
1. Persistent Net Loss: Despite the strong revenue growth and operational improvements, Zepp Health still recorded a net loss attributable to the company of $1.6 million. While this is a significant improvement from the $13.3 million loss in the same period last year, investors may be looking for a clearer path to profitability.
2. Gross Margin Pressure: The company's gross margin in Q3 2025 was 38.2%, representing a 2.4% decrease compared to 40.6% in Q3 2024. This decline was primarily attributed to lower gross margins related to entry-level products, which could be raising concerns about the company's pricing power and product mix.
3. Q4 Guidance: Zepp Health expects Q4 2025 revenue to be between $82.0 million and $86.0 million, representing a year-over-year increase of 38% to 45%. While this projection indicates continued strong growth, it may have fallen short of some analysts' expectations, potentially contributing to the stock's decline.
As Zepp Health continues its transition towards profitability, investors will likely be closely monitoring the company's ability to balance revenue growth with margin improvement and cost control. The pre-market plunge suggests that despite the positive developments in Q3, the market may require more concrete evidence of sustainable profitability before regaining confidence in the stock.